J-Pharma Co.,Ltd.
520A.T
Tokyo Stock Exchange286.00
JPY
+5.00
- -
J-Pharma Co.,Ltd.
520A.T
(Tokyo Stock Exchange)
Recent
price
286.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- J-Pharma Co., Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture, and distribution of prescription medicines and healthcare products. The company engages in the discovery and commercialization of innovative therapeutics across multiple therapeutic areas, with an emphasis on delivering high-quality pharmaceutical products to domestic and international markets. Main Products and Services: innovative pharmaceutical products; generic and value-added medicines; branded and non-branded drug formulations; active pharmaceutical ingredients (APIs) and intermediates; contract manufacturing and development for external partners; clinical development collaboration services; regulatory affairs and quality assurance support; sales, marketing, and distribution of finished dosage forms; personalized medicine solutions and companion diagnostics; patient support programs and pharmacovigilance services; platform technologies for drug delivery; packaging and labeling services; research and development services, including preclinical and clinical-stage programs; manufacturing of solid oral dosage forms, injectables, and semi-solid formulations; specialty pharmaceutical products targeting oncology, neurology, immunology, and infectious diseases; veterinary medicines and animal health products; distribution logistics and supply chain management. Latest Major Company Changes: announces strategic partnerships with global biotech and pharmaceutical firms to co-develop and co-commercialize therapeutic candidates; completes recent acquisitions to expand manufacturing capacity and diversify product portfolio; launches new oncology and autoimmune disease therapies; expands geographic footprint through new distribution agreements in Asia-Pacific and Europe; undergoes corporate reorganization to streamline operations and enhance R&D focus; appoints new CEO and strengthens board with industry veterans; upgrades GMP-compliant facilities and implements digital transformation across manufacturing and supply chain. Additional Context: Industry and segments include pharmaceuticals, contract development and manufacturing organization (CDMO) services, and specialty medicines; targets healthcare providers, hospitals, pharmaceutical wholesalers, and international partners; operates primarily in Japan with expanding presence in Asia-Pacific, Europe, and North America; founding year and headquarters located in Japan (headquarters in Tokyo prefecture); subsidiaries and potential parent relationships under a corporate group structure.